We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 6 for:    azixa

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00394446
First Posted: November 1, 2006
Last Update Posted: February 13, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Myrexis Inc.
  Purpose
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Condition Intervention Phase
Refractory Solid Tumors Drug: MPC-6827 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.

Further study details as provided by Myrexis Inc.:

Primary Outcome Measures:
  • Maximum Tolerated Dose [ Time Frame: 1 year ]
  • Pharmacokinetics [ Time Frame: 22 months ]

Secondary Outcome Measures:
  • Antitumor Activity [ Time Frame: 2 years ]

Enrollment: 48
Study Start Date: March 2005
Study Completion Date: February 2008
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: MPC-6827
    2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Advanced or Metastatic Cancer
  2. Measurable / Evaluable Disease
  3. Karnofsky score greater than or equal to 70%
  4. Adequate Hematology / Organ function
  5. No Baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

  1. Hypersensitivity to Cremophor EL
  2. Pregnant or Lactating
  3. Spinal Cord Compression
  4. Pre-existing Dementia / Cognitive Disfunction
  5. Require Neupogen or Neulasta to Maintain Neutrophil Count
  6. Have Primary Brain Cancer
  7. Have history of Ischemic Heart Disease
  8. Have Diabetes
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00394446


Locations
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Myrexis Inc.
Investigators
Study Director: Margaret Yu, MD Myrexis Inc.
  More Information

Responsible Party: Margaret Yu, MD / Director of Clinical Research, Myriad Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00394446     History of Changes
Other Study ID Numbers: MPC6827-04-001
First Submitted: October 30, 2006
First Posted: November 1, 2006
Last Update Posted: February 13, 2008
Last Verified: February 2008

Keywords provided by Myrexis Inc.:
Solid Tumors
Refractory
Brain